Co-delivery of resveratrol and p53 gene via peptide cationic liposomal nanocarrier for the synergistic treatment of cervical cancer and breast cancer cells

In our previous study, we have carried out the synthesis of a novel peptide-cationic lipid (CDO14) for gene delivery. Herein, CDO14 liposome was used for co-delivering resveratrol and p53 gene to investigate the gene delivery efficiency of resveratrol liposomes (CDOR) and the anti-tumor effect of CDOR/p53 gene lipoplexes against cervical cancer and breast cancer cells (Hela and MCF-7 cells). The liposomes coating resveratrol were prepared using different weight ratios of CDO14/resveratrol. They were characterized by dynamic laser scattering (DLS), high performance liquid chromatography (HPLC) and agarose gel retardation assay. In vitro transfection studies revealed that the highest transfection efficiency was obtained when lipid/pDNA (N/P) weight ratio was 3/1 and Hela cells showed greater transfection efficiency than MCF-7 cells. MTT assay illustrated that co-delivery systems of reveratrol and p53 had stronger growth inhibition on Hela cells and MCF-7 cells than the blank liposomes and resveratrol liposomes, and MCF-7 cells exhibited lower cell viability than Hela cells. Hoechst 33342 assay indicated that CDOR/p53 lipoplexes were capable of inducing more cell apoptosis. We could conclude that co-delivery of resveratrol and p53 gene via CDO14 liposome may be a potential therapeutic agent for the synergistic treatment of Hela and MCF-7 cells.